ATLASBambusa Therapeutics, Inc. IPO (BBTX)
The data feed lists Bambusa Therapeutics, Inc. for NASDAQ with a start date of Oct 30, 2026, status "Priced", and an offer price of $16.00 per the final prospectus (424B4). First-day change from open to close: +0.7%.
Updated November 4, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation. The company was founded on March 14, 2024 and is advancing lead product candidates BBT001 and BBT002, as well as two preclinical candidates BBT003 and BBT004, targeting dermatology, respiratory, gastroenterology, and autoimmune diseases. It has no approved products and has generated no revenue from product sales.
The offer
- Offer price
- $16.00
- Shares offered
- 10,555,555
- Over-allotment option
- 1,583,333 shares
- Gross proceeds
- $168,888,880
- Net proceeds to the company
- $152.4M ($176.0M with full option)
- Shares outstanding after the offering
- 50,942,430
- Lead underwriters
- BofA Securities, Evercore ISI, UBS Investment Bank, Cantor
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Net income (loss) | -13,741 | -41,087 | -14,747 | -22,360 |
| Cash and equivalents | — | — | — | 46,534 |
| Total assets | — | — | — | 77,496 |
Key risks
No approved products or revenue. Bambusa is a clinical-stage company with no approved products and has generated no revenue from product sales since its inception on March 14, 2024.
Going concern doubt. As of September 30, 2026, the company had approximately $57.2 million of cash, cash equivalents, and marketable securities, which are not expected to be sufficient to fund operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern.
Clinical trial uncertainty. Clinical development is a complex and challenging process with uncertain outcomes and is subject to a number of risks that can cause delays in completing a trial or reaching a milestone on time.
Stock price volatility. The stock market, particularly for pharmaceutical and biotechnology companies, has experienced significant price and volume fluctuations often unrelated to operating performance, which could affect the market price of the company's shares.
Timeline
- Oct 9, 2026 · Registration statement filed (S-1)
- Oct 26, 2026 · Amendment (S-1/A)
- Oct 30, 2026 · Final prospectus (price set) (424B4) View filing
- Nov 3, 2026 · Current report (8-K)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 4, 2026.
Calendar data
| Status in feed | Priced |
|---|---|
| Start date | Oct 30, 2026 |
| Exchange | NASDAQ |
| Shares offered | 10,555,555 |
| First-day change (open to close) | +0.74% |
| First-day open | $14.88 |
| First-day close | $14.99 |
| Filing date | Oct 30, 2026 |
| Last amended | Oct 30, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow BBTX and get one email when it starts trading.
Create an accountFrequently asked questions
What does Bambusa Therapeutics, Inc. do?
Bambusa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation. The company was founded on March 14, 2024 and is advancing lead product candidates BBT001 and BBT002, as well as two preclinical candidates BBT003 and BBT004, targeting dermatology, respiratory, gastroenterology, and autoimmune diseases. It has no approved products and has generated no revenue from product sales.
How much is the Bambusa Therapeutics, Inc. IPO raising?
The final prospectus sets a price of $16.00 per share for 10,555,555 shares, or $168,888,880 before expenses and discounts.
Who are the underwriters of the Bambusa Therapeutics, Inc. IPO?
BofA Securities, Evercore ISI, UBS Investment Bank, Cantor.
When is the Bambusa Therapeutics, Inc. IPO?
The data feed lists a start date of Oct 30, 2026 with status "Priced".
What is the Bambusa Therapeutics, Inc. IPO price range?
According to the final prospectus (424B4), the offer price is $16.00 per share.
How is the first-day change measured?
On the first trading day (Oct 30, 2026) the stock moved +0.74% from its open ($14.88) to its close ($14.99), from daily price data. This is not the change from the IPO offer price.
What does "Priced" mean?
The feed reports the offering as priced. The start date is the first trading day.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer